Cargando…

A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine

BACKGROUND: Lenalidomide (LND) is a potent novel thalidomide analog which demonstrated remarkable clinical activity in treatment of multiple myeloma disease via a multiple-pathways mechanism. The strong evidences-based clinical success of LND in patients has led to its recent approval by US-FDA unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Darwish, Ibrahim A, Khalil, Nasr Y, Bakheit, Ahmed H, Alzoman, Nourh Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537752/
https://www.ncbi.nlm.nih.gov/pubmed/23068782
http://dx.doi.org/10.1186/1752-153X-6-118
_version_ 1782254910531698688
author Darwish, Ibrahim A
Khalil, Nasr Y
Bakheit, Ahmed H
Alzoman, Nourh Z
author_facet Darwish, Ibrahim A
Khalil, Nasr Y
Bakheit, Ahmed H
Alzoman, Nourh Z
author_sort Darwish, Ibrahim A
collection PubMed
description BACKGROUND: Lenalidomide (LND) is a potent novel thalidomide analog which demonstrated remarkable clinical activity in treatment of multiple myeloma disease via a multiple-pathways mechanism. The strong evidences-based clinical success of LND in patients has led to its recent approval by US-FDA under the trade name of Revlimid® capsules by Celgene Corporation. Fluorimetry is a convenient technique for pharmaceutical quality control, however there was a fluorimetric method for determination of LND in its bulk and capsules. RESULTS: A novel highly sensitive and simple fluorimetric method has been developed and validated for the determination of lenalidmide (LND) in its bulk and dosage forms (capsules). The method was based on nucleophilic substitution reaction of LND with fluorescamine (FLC) in aqueous medium to form a highly fluorescent derivative that was measured at 494 nm after excitation at 381 nm. The factors affecting the reaction were carefully studied and optimized. The kinetics of the reaction was investigated, and the reaction mechanism was postulated. Under the optimized conditions, linear relationship with good correlation coefficient (0.9999) was found between the fluorescence intensity and LND concentration in the range of 25–300 ng/mL. The limits of detection and quantitation for the method were 2.9 and 8.7 ng/mL, respectively. The precision of the method was satisfactory; the values of relative standard deviations did not exceed 1.4%. The proposed method was successfully applied to the determination of LND in its bulk form and pharmaceutical capsules with good accuracy; the recovery values were 97.8–101.4 ± 1.08–2.75%. CONCLUSIONS: The proposed method is selective and involved simple procedures. In conclusion, the method is practical and valuable for routine application in quality control laboratories for determination of LND.
format Online
Article
Text
id pubmed-3537752
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35377522013-01-10 A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine Darwish, Ibrahim A Khalil, Nasr Y Bakheit, Ahmed H Alzoman, Nourh Z Chem Cent J Research Article BACKGROUND: Lenalidomide (LND) is a potent novel thalidomide analog which demonstrated remarkable clinical activity in treatment of multiple myeloma disease via a multiple-pathways mechanism. The strong evidences-based clinical success of LND in patients has led to its recent approval by US-FDA under the trade name of Revlimid® capsules by Celgene Corporation. Fluorimetry is a convenient technique for pharmaceutical quality control, however there was a fluorimetric method for determination of LND in its bulk and capsules. RESULTS: A novel highly sensitive and simple fluorimetric method has been developed and validated for the determination of lenalidmide (LND) in its bulk and dosage forms (capsules). The method was based on nucleophilic substitution reaction of LND with fluorescamine (FLC) in aqueous medium to form a highly fluorescent derivative that was measured at 494 nm after excitation at 381 nm. The factors affecting the reaction were carefully studied and optimized. The kinetics of the reaction was investigated, and the reaction mechanism was postulated. Under the optimized conditions, linear relationship with good correlation coefficient (0.9999) was found between the fluorescence intensity and LND concentration in the range of 25–300 ng/mL. The limits of detection and quantitation for the method were 2.9 and 8.7 ng/mL, respectively. The precision of the method was satisfactory; the values of relative standard deviations did not exceed 1.4%. The proposed method was successfully applied to the determination of LND in its bulk form and pharmaceutical capsules with good accuracy; the recovery values were 97.8–101.4 ± 1.08–2.75%. CONCLUSIONS: The proposed method is selective and involved simple procedures. In conclusion, the method is practical and valuable for routine application in quality control laboratories for determination of LND. BioMed Central 2012-10-16 /pmc/articles/PMC3537752/ /pubmed/23068782 http://dx.doi.org/10.1186/1752-153X-6-118 Text en Copyright ©2012 Darwish et al.; licensee Chemistry Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Darwish, Ibrahim A
Khalil, Nasr Y
Bakheit, Ahmed H
Alzoman, Nourh Z
A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine
title A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine
title_full A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine
title_fullStr A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine
title_full_unstemmed A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine
title_short A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine
title_sort highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537752/
https://www.ncbi.nlm.nih.gov/pubmed/23068782
http://dx.doi.org/10.1186/1752-153X-6-118
work_keys_str_mv AT darwishibrahima ahighlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine
AT khalilnasry ahighlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine
AT bakheitahmedh ahighlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine
AT alzomannourhz ahighlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine
AT darwishibrahima highlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine
AT khalilnasry highlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine
AT bakheitahmedh highlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine
AT alzomannourhz highlysensitivefluorimetricmethodfordeterminationoflenalidomideinitsbulkformandcapsulesviaderivatizationwithfluorescamine